Wells Fargo & Company Age X Therapeutics, Inc. Transaction History

Wells Fargo & Company

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.33 - $0.74 $10 - $23	-32 Reduced 6.44%	465 $0
Q3 2023 Nov 13, 2023	BUY	$0.67 - $0.85 $1 - $1	2 Added 0.4%	497 $0
Q2 2023 Aug 15, 2023	SELL	$0.45 - $0.89 $141 - $279	-314 Reduced 38.81%	495 $0
Q1 2023 May 12, 2023	BUY	$0.56 - $0.8 $1 - $2	3 Added 0.37%	809 $0
Q4 2022 Feb 13, 2023	BUY	$0.54 - $0.68 $1 - $2	3 Added 0.37%	806 $0
Q3 2022 Nov 14, 2022	SELL	$0.55 - $0.74 $0 - $0	-1 Reduced 0.12%	803 $0
Q2 2022 Aug 12, 2022	BUY	$0.57 - $1.0 $120 - $212	212 Added 35.81%	804 $0
Q3 2021 Nov 15, 2021	SELL	$0.93 - $1.54 $189 - $314	-204 Reduced 25.63%	592 $0
Q1 2021 May 13, 2021	BUY	$1.56 - $2.7 $499 - $864	320 Added 67.23%	796 $1,000
Q4 2020 Feb 09, 2021	BUY	$0.8 - $2.56 $6 - $20	8 Added 1.71%	476 $0
Q3 2020 Nov 05, 2020	SELL	$0.79 - $1.52 $275 - $530	-349 Reduced 42.72%	468 $0
Q2 2020 Aug 13, 2020	SELL	$0.68 - $1.13 $29,686 - $49,332	-43,657 Reduced 98.16%	817 $0
Q1 2020 May 14, 2020	BUY	$0.78 - $1.95 $34,689 - $86,724	44,474 New	44,474 $41,000

Ticker AGE
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,945,100
Description
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-rel...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.